Krystal Biotech
KRYS
334 hedge funds and large institutions have $7.02B invested in Krystal Biotech in 2025 Q4 according to their latest regulatory filings, with 82 funds opening new positions, 112 increasing their positions, 104 reducing their positions, and 27 closing their positions.
204% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 27
145% more call options, than puts
Call options by funds: $53M | Put options by funds: $21.6M
42% more capital invested
Capital invested by funds: $4.94B → $7.02B (+$2.08B)
18% more funds holding
Funds holding: 284 → 334 (+50)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
1.39% more ownership
Funds ownership: 96.77% → 98.16% (+1.4%)
8% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 104
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$86.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$47.8M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$44.1M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$23.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$22.3M |
Top Sellers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$67M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$52.7M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$42.1M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$35.6M |
| 5 |
Millennium Management
New York
|
-$28.2M |
KRYS Hedge Fund Activity: Q4 2025 in Review
334 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2025, worth a combined $7.02B — up 42% from $4.94B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new KRYS positions and 27 closed out — a net gain of 55 holders — while 112 added to existing stakes and 104 trimmed.
The largest buyer was Bellevue Group, adding an estimated $86.1M. The largest seller was Braidwell, cutting an estimated $67M.
- 334 institutional investors held Krystal Biotech (KRYS) as of Q4 2025, up from 284 in Q3 2025.
- Funds reported $7.02B of Krystal Biotech stock for Q4 2025, up 42% quarter-over-quarter.
- 82 funds opened new Krystal Biotech positions in Q4 2025 and 27 closed out, a net change of +55 holders.
- The largest Krystal Biotech buyer in Q4 2025 was Bellevue Group, an estimated $86.1M added.
- The largest Krystal Biotech seller in Q4 2025 was Braidwell, an estimated $67M sold.
Based on aggregated 13F filings for Q4 2025.